研究目的
To develop and validate SERS-based nanoprobes for the detection and quantification of PSMA at the single-cell level and in prostate tissue microarrays, aiming to improve prostate cancer patient stratification and personalized therapeutic protocols.
研究成果
The study confirms PSMA as an effective biomarker for prostate cancer evaluation and demonstrates the potential of SERS-based techniques for improved patient stratification and personalized treatment planning. The method allows for detailed quantification of biomarker expression, offering advantages over traditional fluorescence-based immunohistochemistry.
研究不足
The study is a retrospective analysis with a limited number of prostate cancer patients. The approach has not been included in clinical trials yet.
1:Experimental Design and Method Selection:
The study employed SERS nanoprobes functionalized with PSMA aptamer molecules for PSMA detection and quantification. Gold nanostars were synthesized and functionalized with a Raman reporter and PSMA aptamer.
2:Sample Selection and Data Sources:
Prostate cancer cells (LNCaP and PC3) and prostate tissue microarrays from 34 patients with different clinical stagings were used.
3:List of Experimental Equipment and Materials:
Gold nanostars, 4-aminothiophenol (4-ATP), PSMA aptamer, tissue culture plates, transmission electron microscope, UV-vis spectrophotometer, dynamic light scattering instrument, Zetasizer, Renishaw in Via Raman microscope.
4:Experimental Procedures and Operational Workflow:
Synthesis and functionalization of gold nanostars, preparation of SERS tags, SERS measurements on cells and tissue microarrays, immunofluorescence staining for comparison.
5:Data Analysis Methods:
SERS data were analyzed using Raman microscopy, with statistical analyses performed using ANOVA in Origin 9.5 software.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容